U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07179042) titled 'Intertrochanteric Femur Fracture Patients Who Receive Metformin With a Placebo' on Sept. 10.
Brief Summary: The investigators central hypothesis is that metformin supplementation will be well-tolerated, safe, and provide patients with improved functional and muscle morphology outcomes following intertrochanteric femur fracture. The objectives will be tested in older adults that sustain a hip fracture and are randomized to receive a daily oral dose (1.5g daily) of metformin or a non-active placebo during 4 months of recovery following surgery.
Study Start Date: Sept. 04
Study Type: INTERVENTIONAL
Condition:
Intertrochanteric Fem...